COMMUNIQUÉS West-GlobeNewswire

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis
22/06/2026
Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries Recently completed Phase 1 Single Ascending Dose study of PRO-203 in healthy volunteers Investigator- [...]
Catheter Precision, Inc. Announces Allowance of Key Intellectual Property
22/06/2026
Eight New Patents Issued on Heart Failure Technology Three New Patents Granted on Vascular Closure Technology FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today [...]
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
22/06/2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
22/06/2026
FAIR HAVEN, N.J. and ITHACA, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- TETmedical, Inc., a clinical stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury based on its patented [...]
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
22/06/2026
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
22/06/2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026 [...]
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
22/06/2026
– Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors – First patient dosed in Phase 1b/2a ALS study with NB-4746, an oral, brain-penetrant SARM1 inhibitor – Dosing initiated in a first-in- [...]
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
22/06/2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Clariane has launched a proposed offering of €333 million of undated deeply subordinated hybrid notes to refinance its ODIRNANE
22/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Clariane annonce le lancement d’une offre de 333 millions d’euros d’obligations hybrides à durée indéterminée subordonnées de dernier rang en vue du refinancement de ses ODIRNANE
22/06/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
22/06/2026
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches late-stage development [...]
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
22/06/2026
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as a DLL3 biomarker- [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
22/06/2026
COPENHAGEN, Denmark, June 22, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
CARBIOS présente les résultats de son Assemblée Générale du 18 juin 2026
22/06/2026
Clermont-Ferrand (France), le 22 juin 2026 (7h45 CEST). CARBIOS, (Euronext Growth Paris : ALCRB) annonce les résultats de son Assemblée Générale Ordinaire Annuelle et Extraordinaire du 18 juin 2026. Les actionnaires [...]
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
22/06/2026
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026 . Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, Global Head of Research [...]
SKG Brings Deep Recovery Technology to Father’s Day Gifting
22/06/2026
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- This Father’s Day, SKG is bringing smart recovery to the top of the gift list with wearable smart massagers designed for dads’ everyday routines. As thoughtful gift options, [...]
CARBIOS presents the results of its Annual General Meeting of June 18, 2026
22/06/2026
Clermont-Ferrand (France), June 22, 2026 (7:45 am CEST). CARBIOS , (Euronext Growth Paris: ALCRB), announces the results of its Annual Ordinary and Extraordinary General Meeting held on June 18, 2026. Shareholders [...]
Communiqué de presse : Sanofi nomme Paulo Fontoura à la tête de sa R&D
22/06/2026
Sanofi nomme Paulo Fontoura à la tête de sa R&D Paris , 22 juin 2026. Sanofi annonce la nomination du Dr Paulo Fontoura au poste de Vice-Président Exécutif, Responsable mondial de la Recherche & Développement [...]
Pharmacy automation interoperability: Deenova to deliver an integrated medication management platform at Policlinico di Milano
22/06/2026
MILAN, June 22, 2026 (GLOBE NEWSWIRE) -- Deenova announces the launch of activities for the implementation of a new integrated system for the automation and traceability of medication management at Fondazione IRCCS Ca’ [...]

Pages